​

GlycoMimetics (GLYC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GLYC Stock Forecast

GlycoMimetics stock forecast is as follows: a rating consensus of 'Hold', based on 2 wall street analysts offering a 1-year stock forecast.

GLYC Analyst Ratings

Hold

According to 2 Wall Street analysts, GlycoMimetics's rating consensus is 'Hold'. The analyst rating breakdown for GLYC stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 2 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Jul 26, 2024Cowen & Co.HoldDowngrade
May 06, 2024H.C. WainwrightNeutralDowngrade

GlycoMimetics's last stock rating was published by Cowen & Co. on Jul 26, 2024. The company Downgrade its GLYC rating from "null" to "Hold".

GlycoMimetics Financial Forecast

GlycoMimetics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 23Mar 21Dec 20Mar 20
Revenue--------$1.06M$162.94K$9.00M
Avg Forecast-------$50.00K$1.19M$333.33K$15.00M
High Forecast-------$50.00K$1.42M$333.33K$18.00M
Low Forecast-------$50.00K$949.90K$333.33K$12.00M
# Analysts-------1201018
Surprise %--------0.89%0.49%0.60%

GlycoMimetics's average Quarter revenue forecast for Jun 23 based on 1 analysts is $50.00K, with a low forecast of $50.00K, and a high forecast of $50.00K. GLYC's average Quarter revenue forecast represents a -95.26% decrease compared to the company's last Quarter revenue of $1.06M (Mar 21).

GlycoMimetics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 23Mar 21Dec 20Mar 20
# Analysts-------1201018
EBITDA-------$-8.93B$-14.21M$-15.49M$-7.59M
Avg Forecast-------$-30.00K$-15.98M$-200.00K$-10.63M
High Forecast-------$-30.00K$-12.79M$-200.00K$-8.51M
Low Forecast-------$-30.00K$-19.18M$-200.00K$-12.76M
Surprise %-------297664.83%0.89%77.47%0.71%

undefined analysts predict GLYC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than GlycoMimetics's previous annual EBITDA (undefined) of $NaN.

GlycoMimetics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 23Mar 21Dec 20Mar 20
# Analysts-------1201018
Net Income--------$-14.27M$-15.56M$-7.66M
Avg Forecast$-22.57M$-12.90M$-12.90M$-9.67M$-5.80M$-7.09M$-10.80M$-11.82M$-16.06M$-20.25M$-10.73M
High Forecast$-22.57M$-12.90M$-12.90M$-9.67M$-5.80M$-7.09M$-10.80M$-11.82M$-12.85M$-20.25M$-8.58M
Low Forecast$-22.57M$-12.90M$-12.90M$-9.67M$-5.80M$-7.09M$-10.80M$-11.82M$-19.27M$-20.25M$-12.87M
Surprise %--------0.89%0.77%0.71%

GlycoMimetics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GLYC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

GlycoMimetics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 23Mar 21Dec 20Mar 20
# Analysts-------1201018
SG&A-------$4.86B$4.19M$4.01M$4.44M
Avg Forecast-------$21.94M$517.26M$145.21M$6.22M
High Forecast-------$21.94M$620.71M$145.21M$7.46M
Low Forecast-------$21.94M$413.81M$145.21M$4.97M
Surprise %-------221.44%0.01%0.03%0.71%

GlycoMimetics's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to GLYC last annual SG&A of $4.86B (Jun 23).

GlycoMimetics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Jun 23Mar 21Dec 20Mar 20
# Analysts-------1201018
EPS--------$-0.28$-0.32$-0.18
Avg Forecast$-0.35$-0.20$-0.20$-0.15$-0.09$-0.11$-0.17$-0.18$-0.31$-0.31$-0.30
High Forecast$-0.35$-0.20$-0.20$-0.15$-0.09$-0.11$-0.17$-0.18$-0.31$-0.31$-0.30
Low Forecast$-0.35$-0.20$-0.20$-0.15$-0.09$-0.11$-0.17$-0.18$-0.31$-0.31$-0.30
Surprise %--------0.90%1.02%0.61%

According to undefined Wall Street analysts, GlycoMimetics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GLYC previous annual EPS of $NaN (undefined).

GlycoMimetics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
GLYCGlycoMimetics$0.23$13.005552.17%
IVAInventiva$2.28$36.001478.95%Buy
SPROSpero Therapeutics$1.04$10.00861.54%Buy
TILInstil Bio$21.69$150.00591.56%Hold
BCABBioAtla$1.31$5.00281.68%Buy
ANTXAN2 Therapeutics$1.34$5.00273.13%Buy
CUECue Biopharma$1.06$3.00183.02%Buy
FHTXFoghorn Therapeutics$5.51$14.00154.08%Buy
ASMBAssembly Biosciences$14.28$35.50148.60%Buy
MLYSMineralys Therapeutics$12.35$30.00142.91%Buy
ACHLAchilles Therapeutics$0.97$2.00106.19%Buy
DYNDyne Therapeutics$26.16$49.0087.31%Buy
TRVITrevi Therapeutics$4.50$6.0033.33%Buy

GLYC Forecast FAQ

Is GlycoMimetics a good buy?

No, according to 2 Wall Street analysts, GlycoMimetics (GLYC) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of GLYC's total ratings.

What are GlycoMimetics's analysts' financial forecasts?

GlycoMimetics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-23.698M (high $-23.698M, low $-23.698M), average SG&A $0 (high $0, low $0), and average EPS is $-0.368 (high $-0.368, low $-0.368). GLYC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-58.036M (high $-58.036M, low $-58.036M), average SG&A $0 (high $0, low $0), and average EPS is $-0.9 (high $-0.9, low $-0.9).

Did the GLYC's actual financial results beat the analysts' financial forecasts?

Based on GlycoMimetics's last annual report (Dec 2020), the company's revenue was $10.16M, which missed the average analysts forecast of $15.33M by -33.72%. Apple's EBITDA was $-51.509M, beating the average prediction of $-10.832M by 375.52%. The company's net income was $-50.274M, beating the average estimation of $-30.976M by 62.30%. Apple's SG&A was $16.74M, missing the average forecast of $151.43M by -88.94%. Lastly, the company's EPS was $-1.1, beating the average prediction of $-0.61 by 80.33%. In terms of the last quarterly report (Mar 2021), GlycoMimetics's revenue was $1.06M, missing the average analysts' forecast of $1.19M by -11.11%. The company's EBITDA was $-14.206M, missing the average prediction of $-15.982M by -11.11%. GlycoMimetics's net income was $-14.274M, missing the average estimation of $-16.058M by -11.11%. The company's SG&A was $4.19M, missing the average forecast of $517.26M by -99.19%. Lastly, the company's EPS was $-0.28, missing the average prediction of $-0.31 by -9.68%